S&P 500   3,388.90 (+0.55%)
DOW   29,366.60 (+0.46%)
QQQ   237.01 (+0.97%)
AAPL   323.97 (+1.56%)
FB   217.46 (-0.16%)
MSFT   187.06 (-0.09%)
GOOGL   1,528.38 (+0.59%)
AMZN   2,180.90 (+1.17%)
CGC   21.90 (-0.23%)
NVDA   311.31 (+4.97%)
BABA   221.83 (+0.59%)
MU   59.12 (+2.37%)
GE   12.88 (+1.02%)
TSLA   938.64 (+9.35%)
AMD   59.06 (+3.80%)
T   38.43 (+0.44%)
ACB   1.71 (+4.28%)
NFLX   387.70 (-0.02%)
BAC   34.72 (+1.31%)
DIS   140.91 (+1.27%)
GILD   66.91 (-0.16%)
S&P 500   3,388.90 (+0.55%)
DOW   29,366.60 (+0.46%)
QQQ   237.01 (+0.97%)
AAPL   323.97 (+1.56%)
FB   217.46 (-0.16%)
MSFT   187.06 (-0.09%)
GOOGL   1,528.38 (+0.59%)
AMZN   2,180.90 (+1.17%)
CGC   21.90 (-0.23%)
NVDA   311.31 (+4.97%)
BABA   221.83 (+0.59%)
MU   59.12 (+2.37%)
GE   12.88 (+1.02%)
TSLA   938.64 (+9.35%)
AMD   59.06 (+3.80%)
T   38.43 (+0.44%)
ACB   1.71 (+4.28%)
NFLX   387.70 (-0.02%)
BAC   34.72 (+1.31%)
DIS   140.91 (+1.27%)
GILD   66.91 (-0.16%)
S&P 500   3,388.90 (+0.55%)
DOW   29,366.60 (+0.46%)
QQQ   237.01 (+0.97%)
AAPL   323.97 (+1.56%)
FB   217.46 (-0.16%)
MSFT   187.06 (-0.09%)
GOOGL   1,528.38 (+0.59%)
AMZN   2,180.90 (+1.17%)
CGC   21.90 (-0.23%)
NVDA   311.31 (+4.97%)
BABA   221.83 (+0.59%)
MU   59.12 (+2.37%)
GE   12.88 (+1.02%)
TSLA   938.64 (+9.35%)
AMD   59.06 (+3.80%)
T   38.43 (+0.44%)
ACB   1.71 (+4.28%)
NFLX   387.70 (-0.02%)
BAC   34.72 (+1.31%)
DIS   140.91 (+1.27%)
GILD   66.91 (-0.16%)
S&P 500   3,388.90 (+0.55%)
DOW   29,366.60 (+0.46%)
QQQ   237.01 (+0.97%)
AAPL   323.97 (+1.56%)
FB   217.46 (-0.16%)
MSFT   187.06 (-0.09%)
GOOGL   1,528.38 (+0.59%)
AMZN   2,180.90 (+1.17%)
CGC   21.90 (-0.23%)
NVDA   311.31 (+4.97%)
BABA   221.83 (+0.59%)
MU   59.12 (+2.37%)
GE   12.88 (+1.02%)
TSLA   938.64 (+9.35%)
AMD   59.06 (+3.80%)
T   38.43 (+0.44%)
ACB   1.71 (+4.28%)
NFLX   387.70 (-0.02%)
BAC   34.72 (+1.31%)
DIS   140.91 (+1.27%)
GILD   66.91 (-0.16%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Stemline TherapeuticsCue BiopharmaOptiNose89bioSyros Pharmaceuticals
SymbolNASDAQ:STMLNASDAQ:CUENASDAQ:OPTNNASDAQ:ETNBNASDAQ:SYRS
Price Information
Current Price$7.22$19.09$7.55$36.14$7.29
52 Week RangeBuyBuyBuyBuyBuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$21.50$13.00$24.83$47.80$13.83
% Upside from Price Target197.78% upside-31.90% downside228.92% upside32.26% upside89.76% upside
Trade Information
Market Cap$353.92 million$416.58 million$285.25 million$466.45 million$334.01 million
Beta1.431.660.78N/A1.58
Average Volume663,819200,599174,24748,397165,071
Sales & Book Value
Annual Revenue$500,000.00$1.14 million$7.07 millionN/A$2.05 million
Price / Sales723.88384.9844.40N/A150.92
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.32 per share$1.64 per share$2.88 per shareN/A$2.34 per share
Price / Book5.4711.642.62N/A3.12
Profitability
Net Income$-85,020,000.00$-38,980,000.00$-106,660,000.00N/A$-62,280,000.00
EPS($2.99)($1.94)($2.68)N/A($1.91)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-1,437.96%-419.37%N/A-3,115.38%
Return on Equity (ROE)-80.29%-148.66%-137.60%N/A-84.49%
Return on Assets (ROA)-65.23%-88.78%-61.40%N/A-60.09%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.10%1.67%N/A0.20%
Current Ratio8.75%3.17%4.81%N/A4.92%
Quick Ratio8.63%3.17%4.66%N/A4.92%
Ownership Information
Institutional Ownership Percentage85.98%27.80%71.64%N/AN/A
Insider Ownership Percentage13.10%16.80%44.30%N/A14.80%
Miscellaneous
Employees92461021376
Shares Outstanding50.13 million22.99 million41.58 million12.99 million42.44 million
Next Earnings Date3/20/2020 (Estimated)3/12/2020 (Estimated)3/4/2020 (Estimated)3/18/2020 (Estimated)3/5/2020 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel